An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 Feb 15

PMID 30761212

Citations 13

Authors

Naim Alkhouri

Andrea Scott

Affiliations

Soon will be listed here.

Citing Articles

Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials.

Han T, Yang W, Tan Q, Bai S, Zhong H, Tai Y Front Microbiol. 2023; 13:1004911.

PMID: 36726574 PMC: 9884806. DOI: 10.3389/fmicb.2022.1004911.

Loss of hepatic phosphoenolpyruvate carboxykinase 1 dysregulates metabolic responses to acute exercise but enhances adaptations to exercise training in mice.

Rome F, Shobert G, Voigt W, Stagg D, Puchalska P, Burgess S Am J Physiol Endocrinol Metab. 2022; 324(1):E9-E23.

PMID: 36351254 PMC: 9799143. DOI: 10.1152/ajpendo.00222.2022.

Effectiveness and safety of Shugan Jianpi (SGJP) formula in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review and meta-analysis of randomized controlled trials.

Chen M, Gu Y, Huang F, Zhong G, Men L, Liu Q Medicine (Baltimore). 2021; 100(51):e28366.

PMID: 34941156 PMC: 8702140. DOI: 10.1097/MD.0000000000028366.

Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways.

Yasmin T, Rahman M, Khan F, Kabir F, Nahar K, Lasker S Biochem Biophys Rep. 2021; 28:101168.

PMID: 34825068 PMC: 8605070. DOI: 10.1016/j.bbrep.2021.101168.

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling.

Ma N, Wang Y, Xu S, Ni Q, Zheng Q, Zhu B Nat Commun. 2021; 12(1):3059.

PMID: 34031390 PMC: 8144412. DOI: 10.1038/s41467-021-23285-8.

References

Hayakawa R, Hayakawa T, Takeda K, Ichijo H . Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88(8):434-53. PMC: 3491083. DOI: 10.2183/pjab.88.434. View

Grygiel-Gorniak B . Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J. 2014; 13:17. PMC: 3943808. DOI: 10.1186/1475-2891-13-17. View

Neuschwander-Tetri B, Loomba R, Sanyal A, Lavine J, Van Natta M, Abdelmalek M . Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2014; 385(9972):956-65. PMC: 4447192. DOI: 10.1016/S0140-6736(14)61933-4. View

Carr R, Reid A . FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015; 17(4):500. DOI: 10.1007/s11883-015-0500-2. View

Ali A, Carey E, Lindor K . Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015; 3(1):5. PMC: 4293481. DOI: 10.3978/j.issn.2305-5839.2014.12.06. View

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L . Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2):367-78.e5. DOI: 10.1053/j.gastro.2015.04.005. View

Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L . Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016; 150(5):1147-1159.e5. DOI: 10.1053/j.gastro.2016.01.038. View

Alkhouri N, Feldstein A . Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. Metabolism. 2016; 65(8):1087-95. PMC: 4931968. DOI: 10.1016/j.metabol.2016.01.013. View

Lefebvre E, Moyle G, Reshef R, Richman L, Thompson M, Hong F . Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016; 11(6):e0158156. PMC: 4922569. DOI: 10.1371/journal.pone.0158156. View

10.

Rotman Y, Sanyal A . Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2016; 66(1):180-190. DOI: 10.1136/gutjnl-2016-312431. View

11.

Townsend S, Newsome P . Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017; 46(5):494-507. DOI: 10.1111/apt.14210. View

12.

Friedman S, Ratziu V, Harrison S, Abdelmalek M, Aithal G, Caballeria J . A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2017; 67(5):1754-1767. PMC: 5947654. DOI: 10.1002/hep.29477. View

13.

Loomba R, Lawitz E, Mantry P, Jayakumar S, Caldwell S, Arnold H . The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2017; 67(2):549-559. PMC: 5814892. DOI: 10.1002/hep.29514. View